Janux Therapeutics, Inc.
JANXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Janux Therapeutics, Inc. focuses on Biotechnology services and products. Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive. The $889.8M market capitalization puts JANX squarely in small-cap range for its industry. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Market Cap
$889.8M
Beta
2.57
P/E (TTM)
—
P/E (Fwd)
-5.26
EPS (TTM)
$-1.84
EPS (Fwd)
$-2.77
ROE
-11.7%
ROA
-9.4%
Cash
$956.4M
Total Debt
$21.6M
Free CF
-$54.0M
52W Change
-41.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $956.4M in cash comfortably exceeding the $21.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$54.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -11.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $8.6M to $10.0M.
A beta of 2.57 means JANX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, JANX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Janux Therapeutics, Inc. and its sector.